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MaBACKGROUND Balloon catheters have been designed to facilitate pulmonary vein (PV) isolation in patients with
paroxysmal atrial ﬁbrillation (AF). The visually guided laser balloon (VGLB) employs laser energy to ablate tissue under
direct visual guidance.
OBJECTIVES This study compared the efﬁcacy and safety of VGLB ablation with standard irrigated radiofrequency
ablation (RFA) during catheter ablation of AF.
METHODS Patients with drug-refractory paroxysmal AF were enrolled in a multicenter, randomized controlled study of
PV isolation using either the VGLB or RFA (control). The primary efﬁcacy endpoint was freedom from protocol-deﬁned
treatment failure at 12 months, including symptomatic AF occurring after the 90-day blanking period. The primary
efﬁcacy and safety endpoints were powered for noninferiority.
RESULTS A total of 353 patients (178 VGLB, 175 control) were randomized at 19 clinical sites. The mean procedure,
ablation, and ﬂuoroscopy times were longer with VGLB compared with controls. The primary efﬁcacy endpoint was met in
61.1% in the VGLB group versus 61.7% in controls (absolute difference 0.6%; lower limit of 95% conﬁdence interval
[CI]: 9.3%; p ¼ 0.003 for noninferiority). The primary adverse event rate was 11.8% in the VGLB group versus 14.5% in
controls (absolute difference 2.8%; upper limit of 95% CI: 3.5; p ¼ 0.002 for noninferiority), and was mainly driven by
cardioversions. Diaphragmatic paralysis was higher (3.5% vs. 0.6%; p ¼ 0.05), but PV stenosis was lower (0.0% vs.
2.9%; p ¼ 0.03) with VGLB.
CONCLUSIONS Despite minimal prior experience, the safety and efﬁcacy of VGLB ablation proved noninferior to RFA
for the treatment of paroxysmal AF. (Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System–Adaptive
Contact [EAS-AC] [HeartLight] in Patients With Paroxysmal Atrial Fibrillation [PAF] [HeartLight]; NCT01456000)
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AND ACRONYM S
AAD = antiarrhythmic drug
AF = atrial ﬁbrillation
AFL = atrial ﬂutter
AT = atrial tachycardia
CI = conﬁdence interval
CMR = cardiac magneticT he mainstay of catheter-based therapy forpatients with paroxysmal atrial ﬁbrillation(AF) is pulmonary vein (PV) isolation (1).
Despite high rates of acute electrical isolation, long-
term efﬁcacy is mainly limited by PV reconnections
(2,3). This may be attributable to the technical difﬁ-
culty in achieving a transmural and contiguous ring
of necrosis around the PVs with point-by-point
ablation. To facilitate this process, balloon cathetersSEE PAGE 1361
resonance imaging
CT = computed tomography
LA = left atrial
PAE = primary adverse
event(s)
PV = pulmonary vein
RFA = radiofrequency ablation
VGLB = visually guided laser
balloonusing a variety of energy sources, including radiofre-
quency, laser, and cryoenergy, have been introduced
(4–6). Although many of these balloon catheters share
similar features, the visually guided laser balloon
(VGLB) is unique in that it uses: 1) a compliant, variable
diameter balloon, thus allowing a single balloon cath-
eter to accommodate multiple PV sizes/shapes; 2) a 2-
F endoscope to provide real-time direct visualization
of the target tissue; and 3) a maneuverable (w30) aim-
ing arc that allows the operator to easily target the loca-
tion of the PV ostium/antrum and titrate the amount of
laser energy delivered.
Clinical experience with the VGLB has been limited
to several single and multicenter nonrandomized
experiences that have demonstrated reasonable
safety and efﬁcacy (6–10). Although the VGLB is
routinely used clinically in Europe, no multicenter,
randomized studies have compared it with other
technologies. Here, we report the ﬁrst prospective,
multicenter, randomized study comparing the safety
and efﬁcacy of the VGLB with standard irrigated
radiofrequency ablation (RFA) in patients with
paroxysmal AF.
METHODS
The study protocol was approved by the institutional
review boards at each of the 21 sites in the United
States. Of these sites, 19 entered the study’s random-
ized phase (Online Appendix). Two sites enrolled
subjects into the training phase of the study but did
not randomize any patients. The study design stipu-
lated that only randomized patients would be
included in the primary analyses. All patients enrolled
in the study provided written informed consent.
Patients with drug-refractory paroxysmal AF were
enrolled in the study. Inclusion criteria included: $2
symptomatic AF episodes ($1min) within the previous
6 months; 1 documented AF episode within the previ-
ous 12 months; and refractory or intolerance to an
antiarrhythmic drug (AAD) (class I, II, or III). The
exclusion criteria included: PV size >35 mm; left atrial
(LA) thrombus; LA diameter >50 mm; left ventricularejection fraction <30%; previous LA ablation
for AF or atrial ﬂutter (AFL); New York Heart
Association class III or IV symptoms; myocar-
dial infarction within the previous 60 days;
unstable angina; cardiac surgery within the
previous 3 months; coronary artery bypass
grafting within the previous 6 months; any
history of cardiac valve surgery; a thrombo-
embolic event within the previous 3 months;
uncontrolled bleeding; active infection; atrial
myxoma; severe pulmonary disease or gas-
trointestinal bleeding; a previous valvular
cardiac surgical procedure; presence of an
implantable cardioverter-deﬁbrillator; women
of childbearing potential who were pregnant,
lactating, or not using adequate birth control;
and inability to be removed from antiar-
rhythmic drug therapy.
STUDY PROTOCOL. Patients were randomized in
a 1:1 manner to VGLB ablation or RFA (control).
After randomization, patients underwent ablation ac-
cording to their assignment. Following hospital dis-
charge, telephone follow-up was performed at 1 week.
Follow-up visits occurred at 1, 3, 6, and 12 months and
included 12-lead electrocardiogram, physical exami-
nation, and assessment of adverse events. Continued
use of oral anticoagulation therapy was recommended
for 12 months. Use of any U.S. Food and Drug Admin-
istration–approved anticoagulation drug, including
warfarin, dabigatran, or rivaroxaban, was permitted
(apixaban and edoxaban were not approved as
of this study’s initiation). Patients were permitted
to be discharged on the same AAD regimen for
AF that was used pre-procedure until the end of
the 90-day blanking period, at which time it was
discontinued.
All patients were given transtelephonic monitors
before the end of the blanking period, and monitoring
was performed starting at 3 months and continuing
through 12 months. Patients were required to transmit
for all symptoms and also weekly irrespective of
symptoms. Holter monitoring was performed at 6 and
12months. Either a computed tomography (CT) scan or
cardiac magnetic resonance imaging (CMR) was
required within 6 months before enrollment and at
3 months after the procedure. Patients who had ste-
nosis of 1 or more PVs (deﬁned as >50% reduction
in greatest diameter) were also required to have
CT or CMR at 12 months. The National Institutes of
Health Stroke Scale (NIHSS) was administered to
participants before randomization, pre-discharge, and
at the 12-month visit. A safety monitoring committee
reviewed all serious adverse events throughout the
conduct of the study.
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1352ABLATION GROUPS. Anesthesia during cases was
determined by the individual sites, with most using
general anesthesia for all cases. Following transseptal
puncture, a 12-F deﬂectable sheath was positioned at
the LA. In most cases, a second transseptal was per-
formed with an 8-F sheath and was used for a circular
mapping catheter. Intravenous heparin was admin-
istered to maintain an activated clotting time $300 s.
The use of intracardiac echocardiography and eso-
phageal temperature monitoring was mandated by
the protocol.
Ablation was performed with the VGLB system
(HeartLight, CardioFocus, Marlborough, Massachu-
setts). The VGLB catheter is a variable-diameter,
compliant balloon with a ﬂexible tip that is delivered
through a 12-F deﬂectable sheath. Within the central
shaft of the balloon catheter is a 2-F endoscope that
permits real-time visualization of the target tissue. The
central shaft contains lumens for circulating deute-
rium oxide (D2O) to cool the balloon, a maneuverable
optical ﬁber that generates a w30 arc/spot of both
nonablative visible light and near-infrared ablative
light energy. This arc of light can bemaneuvered to any
location along the surface of the balloon to allow aim-
ing and then ablation using diode laser energy (980
nm). The shaft of the catheter contains a radiopaque
marker that can be visualized on ﬂuoroscopy and al-
lows correlation orientation between endoscopic and
ﬂuoroscopic images.
Using the deﬂectable sheath, the VGLB catheter was
inﬂated at the ostium of the target PV. Under visual
guidance, ablation lesions were delivered in a cir-
cumferential, contiguous, and overlapping manner
around the PV. After placement of the initial anatom-
ically guided encircling lesion set, the circular map-
ping catheter was used to assess electrical PV isolation.
If the PVwas not isolated, the VGLB catheter was again
used to deliver lesions to the area of anatomic break-
through. All PVs were targeted in a similar manner.
During ablation of the right superior PV, phrenic nerve
pacing was performed from the superior vena cava to
monitor for phrenic nerve injury. Ablation was termi-
natedwith loss of capture of the phrenic nerve or at any
time when the esophageal temperature exceeded
38.5C. After 30 min post-ablation, PVs were reas-
sessed for electrical isolation with a circular mapping
catheter. Use of isoproterenol was not required by the
protocol.
The typical dose of laser energy used was 8.5 W 
20 s and less commonly, 7, 10, or 12 W per lesion. To
minimize thrombus formation risk, a 5.5 W  30 s dose
was used when ablation was required in regions of
overlapping moving blood along the periphery of the
endoscopic view. Stagnant blood at the center of theendoscopic image represents blood from the target PV
that is completely occluded by the balloon. Ablation
is avoided in this region due to risk of thrombus for-
mation at any laser energy dose. Lesion overlap during
ablation was recommended as 50% for the 5.5 W  30 s
dose and approximately 30% for other doses. Cavo-
tricuspid isthmus ablation using RFA could be per-
formed for participants with a history of typical AFL or
where typical AFL was observed during the procedure.
Other ablation lesion sets were not allowed by
protocol.
Patients randomized to the control arm underwent
ablation using an irrigated RFA catheter (Thermo-
Cool Navistar, Biosense Webster, Diamond Bar, Cal-
ifornia) and CARTO electroanatomic mapping system
(Biosense Webster) guidance. Circumferential abla-
tion was performed to achieve PV isolation. Unique
to the control arm, additional ablation was allowed
at investigator discretion. These could include linear
lesions, ablation of electrogram fractionation, and
cavotricuspid isthmus ablation. Esophageal tem-
perature monitoring was required. After 30 min
post-ablation, PV isolation was reassessed with a
circular mapping catheter. Only entrance block was
required, and veriﬁcation of exit block was optional.
Also unique to the control arm, patients were
allowed a repeat ablation procedure within 80 days
if they had a documented, symptomatic episode
of AF.
EFFICACY AND SAFETY ENDPOINTS. There was a
90-day blanking period for the primary efﬁcacy
endpoint. The primary efﬁcacy endpoint was free-
dom from protocol-deﬁned treatment failure, which
included: 1) documented symptomatic AF ($1 min);
2) ablation-induced LA ﬂutter or atrial tachycardia
(atypical AFL or AT) or AFL/AT of unknown origin;
3) failure to acutely isolate all PVs; 4) use of any
AAD (class I, II, or III); or 5) left heart ablation/surgery
or implantable cardioverter-deﬁbrillator placement
for AF.
All adverse events experienced by patients were
recorded beginning with the ablation procedure
through 12 months of follow-up. Primary adverse
events (PAEs) were deﬁned as: transient ischemic
attack (within 1 month of treatment) or stroke; cardiac
perforation; tamponade; signiﬁcant effusion; PV ste-
nosis; diaphragmatic paralysis (persisting beyond
blanking period); atrio-esophageal ﬁstula; death; ma-
jor bleeding requiring transfusion; myocardial infarc-
tion (Q-wave only—within 1 week of treatment); and
AF/AFL requiring cardioversion.
Additional comparisons between the study groups
included the following pre-speciﬁed secondary end-
points: 1) percentage of patients with all PVs acutely
FIGURE 1 Study Flow
Participants Enrolled
(N=366)
13 Excluded
• 11 did not meet eligibility criteria
    – 4 lack of documented AF
    – 3 did not have PAF
    – 2 left atrial size > 50mm
    – 1 lacked failure of an AAD
    – 1 had condition that might
       compromise patient safety
• 1 withdrew consent
• 1 lack of insurance coverage
Randomized
(N=353)
VGLB (N=178) Control – RF Ablation (N=175)
8 Treatment Not Initiated
• 3 did not meet eligibility criteria
   (documented AF episode, failure of
   AAD, condition that might compromise
   patient safety)
• 2 investigator decision (continued
   alcohol abuse, diagnosis of lung
   cancer)
• 2 console non-operational
• 1 withdrew consent
3 Treatment Not Initiated
• 1 thrombus present on day of
   procedure
• 1 difficulty gaining access
• 1 congenital defect noted during
   procedure
Treated and Evaluable for the
Primary Safety Endpoint (N=170)
Treated and Evaluable for the
Primary Safety Endpoint (N=172)
3 Not Evaluable for Primary Endpoint
• 1 withdrew consent
• 1 missed 12 month visit
• 1 adverse event
5 Not Evaluable for Primary Endpoint
• 2 withdrew consent
• 2 lost to follow-up
• 1 adverse event
Evaluable for Primary Effectiveness
Endpoint (N=167)
Evaluable for Primary Effectiveness
Endpoint (N=167)
Patients with paroxysmal atrial ﬁbrillation (PAF) were randomized to ablation using either the VGLB or a standard irrigated radiofrequency
ablation catheter (control). Primary efﬁcacy was assessed over 12 months of follow-up. AAD ¼ antiarrhythmic drug; RF ¼ radiofrequency;
VGLB ¼ visually guided laser balloon.
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1353isolated; 2) percentage of PVs that remained iso-
lated acutely without reconnection during procedure;
3) rate of chronic/durable PV isolation in patients un-
dergoing second catheter ablation (redo) procedures
during follow-up; and 4) frequency of PV narrowing
and stenosis.
STATISTICAL METHODS. The protocol-deﬁned pri-
mary statistical analysis of the primary endpointswas noninferiority for both safety and efﬁcacy.
Continuous variables are presented as the mean  SD
with 95% conﬁdence intervals (CIs) for the differ-
ences in means, as well as medians and ranges. For
categorical variables, relative frequencies are pro-
vided with 95% CIs for the difference in proportions.
Survival analysis utilized the Kaplan-Meier method.
All tests of signiﬁcance were 2-sided, with p # 0.05
TABLE 1 Patient Demographics
VGLB
(n ¼ 170)
Control
(n ¼ 172) p Value
Age, yrs 59.7  10.4 60.1  8.9 0.69
Sex
Male 118 (69.4) 109 (63.4) 0.24
Female 52 (30.6) 63 (36.6)
Race 0.51
White 164 (96.5) 168 (97.7)
Black 5 (2.9) 0 (0)
Asian 1 (0.6) 2 (1.2)
Other 0 (0) 2 (1.2)
Duration of AF, yrs 2 (IQR 6.25) 3 (IQR 5.67) 0.33
Hypertension 101 (59.4) 100 (58.1) 0.81
Coronary artery disease 36 (21.2) 35 (20.3) 0.85
Myocardial infarction 7 (4.1) 7 (4.1) 0.98
CABG 5 (2.9) 7 (4.1) 0.57
CHF 9 (5.3) 4 (2.3) 0.15
Diabetes mellitus 26 (15.3) 17 (9.9) 0.13
Stroke or TIA 11 (6.5) 13 (7.6) 0.69
Atrial ﬂutter 42 (24.7) 41 (23.8) 0.85
Atrial ﬂutter ablation 15 (8.8) 15 (8.7) 0.97
Ejection fraction, % 60.6  7.4 60.2  7.4 0.60
Left atrial diameter, cm 4.0  0.56 4.0  0.55 0.61
Antiarrhythmic medications —
Class I 84 (49.4) 101 (58.7)
Class II 86 (50.6) 81 (47.1)
Class III 98 (57.6) 99 (57.6)
Values are mean  SD, n (%), or median (IQR).
AF ¼ atrial ﬁbrillation; CABG ¼ coronary artery bypass grafting; CHF ¼ congestive heart failure;
IQR ¼ interquartile range; TIA ¼ transient ischemic attack; VGLB ¼ visually guided laser balloon.
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were conducted using SAS version 9.3 (SAS Institute,
Cary, North Carolina).
The primary safety endpoint was pre-speciﬁed as
a comparison of the rate of patients with 1 or more
PAEs between the 2 groups. The null hypothesis
was the PAE rate for the VGLB was inferior to the
PAE rate for the control device, assuming a non-
inferiority delta of 8.0%. The primary efﬁcacy
endpoint was pre-speciﬁed as a comparison of the
treatment success rates between the groups. For the
primary efﬁcacy endpoint, the null hypothesis was
pre-speciﬁed that the rate of treatment success for
the VGLB was inferior to the success rate of the
control device, assuming a noninferiority delta of
15.0%.
RESULTS
In this study, a total of 342 patients (170 VGLB,
172 controls) underwent ablation, and 334 patients
(167 each group) were evaluable for the primary efﬁ-
cacy endpoint after 12 months of follow-up (Figure 1).PATIENT AND PROCEDURAL CHARACTERISTICS. Of
the 342 patients who underwent ablation, there
were no signiﬁcant differences between the groups
with respect to age, sex, AF duration, LA size,
and left ventricular ejection fraction (Table 1). Pa-
tients who qualiﬁed for the study by failing only
a class II AAD (beta-blocker) represented 11.8%
(20 of 170) and 9.3% (16 of 172) of the enrollments
in the VGLB and control arms, respectively
(p ¼ 0.46).
As shown in Table 2, acute PV isolation was
achieved in 649 of 664 (97.7%) targeted PVs using
the VGLB and in 658 of 664 (99.1%) using the RFA
catheter (p ¼ 0.05). In the VGLB arm, using visual
guidance alone, 583 of 664 (87.8%) PVs were elec-
trically isolated after ﬁrst encirclement. In controls,
for whom ablation was commonly guided by real-
time PV electrogram feedback with a circular map-
ping catheter, 553 of 664 (83.3%) PVs were isolated
after ﬁrst encirclement (p ¼ 0.02). Patients who did
not have all PVs isolated acutely using the random-
ized device represented 5.9% (10 of 170) and 4.1% (7
of 172) of the patients in the VGLB and control arms,
respectively (p ¼ 0.44). The mean number of abla-
tion lesions delivered per PV was 40.1  19.8 for
VGLB, and the mean RF time per PV was 13.0  8.4
min for RFA. The percentage of PVs that reconnected
by the end of the 30-min waiting period was 2.7%
(18 of 664) for VGLB and 5.7% (38 of 664) for RFA
(p ¼ 0.006).
Fluoroscopy, ablation, and procedure times were
all shorter in the control arm. Additional ablation
lesion sets beyond PV isolation were delivered more
frequently in controls compared with the VGLB group
(33.7% vs. 13.5%; p < 0.0001). In the control group, the
protocol permitted redo procedures (within 80 days of
the index procedure) were performed in 2.3% (4 of 172)
of patients.
CLINICAL OUTCOMES. At 12 months, the primary
efﬁcacy endpoint was met in 61.1% in the VGLB group
versus 61.7% in controls (absolute difference: 0.6%;
lower limit of 95% CI: 9.3%; p ¼ 0.003 for non-
inferiority). Figures 2 and 3 show Kaplan-Meier sur-
vival curves and reasons for primary efﬁcacy failure
in each arm, respectively. Overall, 12-month drug-
free rate of freedom from symptomatic AF or
atypical AFL/AT was 63.5% (106 of 167 patients) and
63.9% (106 of 166) in the VGLB and control arms,
respectively (p ¼ 0.94). In patients who underwent
repeat ablation, the rate of durable PV isolation was
52.7% (49 of 93 PVs) for those who initially underwent
VGLB ablation and 46.4% (32 of 69 PVs) in controls
(p ¼ 0.43).
TABLE 2 Procedural Data
VGLB
(n ¼ 170)
Control
(n ¼ 172) p Value
Procedure time, min* 236.0  52.8 193.0  63.6 <0.0001
Ablation time, min† 173.8  46.6 151.2  56.2 <0.0001
Fluoroscopy time, min 35.6  18.2 29.7  21.0 0.006
Number of PVs attempted 3.9  0.4 3.9  0.5 0.34
PVs isolated 649/664 (97.7) 658/664 (99.1) 0.05
PVs isolated on ﬁrst attempt 583/664 (87.8) 553/664 (83.3) 0.02
Attempts per PV to achieve isolation 0.0001
1 583 (89.8) 553 (84.0)
2 45 (6.9) 91 (13.8)
3 15 (2.3) 6 (0.9)
$4 6 (0.9) 8 (1.2)
Number of ablation catheters used 1.2  0.4 1.0  0.2 <0.0001
1 143 (84.1) 167 (97.1) <0.0001
2 26 (15.3) 5 (2.9)
3 1 (0.6) 0 (0.0)
Additional ablation lesions 23 (13.5) 58 (33.7) <0.0001
CTI ablation 21 (12.4) 25 (14.5)
LA roof line 0 (0.0) 20 (11.6)
Mitral isthmus line 1 (0.6) 3 (1.7)
LA septal line 0 (0.0) 5 (2.9)
RA intercaval line 1 (0.6) 1 (0.6)
Other 1 (0.6) 21 (12.2)
Values are mean  SD, n/N (%), or n (%). *Deﬁned as time from venous access to end of last 30-min wait period.
†Deﬁned as time from insertion of catheter to end of last 30-min wait period.
CTI ¼ cavotricuspid isthmus; LA ¼ left atrium; PV ¼ pulmonary vein; RA ¼ right atrium; VGLB ¼ visually guided
laser balloon.
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14.5% in controls (absolute difference: 2.8%; upper
limit of 95% CI: 3.5%; p ¼ 0.002 for noninferiority)
(Table 3). The PAE rate reﬂects the number of patients
experiencing at least 1 PAE rather than the total
number of PAEs. There were a total of 24 PAEs (14.1%)
in the VGLB group and 27 (15.7%) among controls
(p ¼ NS). Diaphragmatic paralysis persisting beyond
the blanking period occurred in 6 (3.5%) and 1 (0.6%)
in the VGLB and control groups, respectively (p ¼
0.05). Of these, 3 (1.8%) persisted at 12 months in the
VGLB group, with 1 resolving after 12 months. The
single diaphragmatic paralysis in the control arm
was persistent at 12 months. There were no in-
stances in which diaphragmatic paralysis occurred
but resolved before procedure conclusion or before
the blanking period ended. At 3 months, CT or CMR
demonstrated a signiﬁcantly higher rate of signiﬁ-
cant PV stenosis (>50% diameter decrease) in con-
trols (2.9% vs. 0.0%; p ¼ 0.03). The rate of PV
narrowing (>20% but #50% diameter decrease,
evaluated on a per-vein basis) was 21.9% in those
who underwent VGLB ablation compared with 24.7%
in controls. There were 2 strokes in the VGLB arm
(1 before discharge, 1 a week after discharge) and 1 in
the control group (p ¼ 0.56). The VGLB patient who
experienced a stroke after discharge was not anti-
coagulated before ablation but received dabigatran
beginning the day of ablation. All 3 strokes com-
pletely resolved. There were no atrio-esophageal
ﬁstulas. There was 1 death in follow-up in the
VGLB arm that was not classiﬁed as a PAE. This was
a patient with severe pulmonary hypertension who
died approximately 7 months after the index proce-
dure and approximately 3 months after an additional
ablation for typical AFL. There were no unanti-
cipated adverse device effects. The NIHSS was
administered pre-treatment, pre-discharge, and at
study exit, and demonstrated no differences be-
tween the groups, with no VGLB patient having a
worsening >1, considered a moderate change using
this assessment tool.
EFFECT OF OPERATOR EXPERIENCE. Because all 30
operators had extensive experience with standard
RFA and limited experience with VGLB, the learning
curve effects were assessed in the latter group
(Figure 4). By study’s end, only 15 of the operators
had performed more than 3 VGLB cases in this study.
The 5 operators with $15 lifetime cases of experience
with VGLB (VGLB-High; 40 cases) were compared
with the 25 operators with <15 lifetime cases of
experience (VGLB-Low; 130 cases). An experience
threshold of 15 cases was selected because it has beenpreviously used to determine the VGLB learning
curve (6). There was a nonsigniﬁcant increase in the
primary efﬁcacy endpoint from 59.4% (VGLB-Low)
to 65.0% (VGLB-High) with increased experience
(p ¼ 0.56). There was also a trend toward more
improved safety with more experience. The PAE
rate was 13.8% in VGLB-Low versus 5.0% in the
VGLB-High groups (p ¼ 0.08). Case times (241.0 
55.0 min vs. 222.0  42.0 min; p ¼ 0.06) and ﬂuo-
roscopy times (38.4  18.6 min vs. 27.3  13.4 min;
p ¼ 0.0003) improved signiﬁcantly with more VGLB
experience. When comparing the VGLB-High group to
controls, the primary efﬁcacy endpoint was nonsig-
niﬁcantly higher in the VGLB-High group (65.0% vs.
61.7%; p ¼ 0.70), and the PAE rate was lower
(5.0% vs. 14.5%; p ¼ 0.10). The overall procedure time
was still lower in controls (222.0  42.0 min vs. 193 
63.6 min; p ¼ 0.006), but ﬂuoroscopy time was lower
(27.3  13.4 min vs. 29.7  21.0 min; p ¼ 0.038) in the
VGLB-High group.
DISCUSSION
This is the ﬁrst multicenter, randomized, controlled
study comparing VGLB ablation versus RFA (con-
trol). The major ﬁnding is that VGLB ablation
FIGURE 2 Primary Efﬁcacy Endpoint
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Per the Kaplan-Meier curves, the primary efﬁcacy endpoint was similar for the VGLB (red)
and control (blue) groups. The abrupt change in both curves at 90 days reﬂects treatment
failure following the end of the blanking period. VGLB ¼ visually guided laser balloon.
FIGURE 3 Causes for Primary Efﬁcacy Endpoint Failure
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The pie charts show treatment success and reasons for failure for the VGLB and control
groups. LA ¼ left atrial; PV ¼ pulmonary vein; other abbreviations as in Figure 1.
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primary efﬁcacy (61.1% vs. 61.7%; p ¼ 0.003 for
noninferiority) and safety (11.8% vs. 14.5%; p ¼
0.002 for noninferiority) endpoints in patients with
paroxysmal AF. These ﬁndings are noteworthy
particularly given the minimal experience of oper-
ators with the VGLB, and the fact that unlike in the
VGLB arm, ancillary ablation beyond PV isolation
and ablation of typical AFL was allowed in controls
as were redo procedures during the blanking period.
There seems to be a learning curve effect with the
VGLB because there was a trend toward improve-
ment in the primary efﬁcacy and adverse event
endpoints with increased VGLB experience ($15
cases) relative to those operators with less experi-
ence (<15 cases) or controls. However, these dif-
ferences did not meet statistical signiﬁcance, likely
due to the sample size for these comparisons.
Although there was no difference in the overall PAE
rate between the VGLB and controls, diaphragmatic
paralysis was more frequent with VGLB ablation
compared with RFA (3.5% vs. 0.6%; p ¼ 0.05), as
seen with other balloon technologies. However, PV
stenosis was more frequent with RFA compared
with the VGLB (0.0% vs. 2.9%; p ¼ 0.03), a ﬁnding
that is atypical for balloon-based ablation.
EFFICACY OF VGLB ABLATION. A component of
the primary efﬁcacy endpoint was freedom from
symptomatic AF or atypical AFL/AT off AADs, which
occurred in 63.5% and 63.9% at 12 months in the
VGLB and control arms, respectively (p ¼ 0.94).
These outcomes with the VGLB are impressive,
given the aforementioned inexperience of the op-
erators and a study protocol that favored controls
because of the ability to perform ancillary ablation
and redo procedures during the blanking period.
However, it should be noted that the RFA catheter
used in this study did not incorporate contact force
information, which has been shown to improve AF
ablation efﬁcacy, particularly when contact force is
optimized (11).
This early experience with the VGLB compares
favorably with that seen with the early cryoballoon
experience in the STOP AF (Sustained Treatment
of Paroxysmal Atrial Fibrillation) study (4) (Central
Illustration). The drug-free single-procedure rate of
freedom from symptomatic AF or atypical AFL/AT at
12 months was 57.7% in that study versus 63.5% with
VGLB in this study. Furthermore, only 83% were able
to achieve isolation with the cryoballoon alone; addi-
tional “spot” ablation was required in the remaining
patients. In the present study, 94.1% of patients were
able to achieve electrical isolation of all PVs with the
TABLE 3 Primary Adverse Events
VGLB
(n ¼ 170)
Control
(n ¼ 172) p Value
Stroke 2 (1.2) 1 (0.6) 0.56
TIA 0 (0.0) 0 (0.0) —
Cardiac tamponade, perforation, or signiﬁcant effusion 2 (1.2) 3 (1.7) 0.66
Diaphragmatic paralysis 6 (3.5) 1 (0.6) 0.05
Atrio-esophageal ﬁstula 0 (0.0) 0 (0.0) —
PV stenosis >50% 0 (0.0) 5 (2.9) 0.03
Cardioversion for atrial arrhythmias 14 (8.2) 16 (9.3) 0.73
Major bleeding requiring transfusion 0 (0.0) 1 (0.6) 0.32
Myocardial infarction 0 (0.0) 0 (0.0) —
Death 0 (0.0) 0 (0.0) —
Total PAEs 24 (14.1) 27 (15.7) NS
Total PAE rate* 20 (11.8) 25 (14.5)
Values are n (%). *The total PAE rate reﬂects the number of patients experiencing a PAE rather than the total of
the number of PAEs.
PAE ¼ primary adverse event(s); other abbreviations as in Tables 1 and 2.
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1357VGLB alone. Although themean procedure (236 vs. 193
min) and ﬂuoroscopy (36 vs. 30 min) times were
signiﬁcantly greater with the VGLB compared with
conventional RFA, these, too, were much shorter
when compared with the STOP AF experience, which
reported mean procedure and ﬂuoroscopy times of 371
min and 63 min with the cryoballoon, respectively. It
should be noted that the STOP AF trial was performed
with the ﬁrst-generation cryoballoon. Subsequent
studies with increased operator experience with this
ﬁrst-generation balloon, as well as a newer second-
generation balloon, demonstrate improved proce-
dure/ﬂuoroscopy times, ability to isolate PVs, and ef-
ﬁcacy compared with the initial STOP AF experience
(12–14).
SAFETY OF VGLB ABLATION. The PAE rates were
lower with the VGLB compared with controls, which
fulﬁlled the pre-speciﬁed criteria to for noninferiority
(11.8% vs. 14.5%; p ¼ 0.002 for noninferiority). These
event rates were primarily driven by an 8.2% and a
9.3% rate of cardioversions in the VGLB and control
arms, respectively. Stroke rates were 1.2% for the
VGLB group and 0.6% in controls (p ¼ 0.56).
Phrenic nerve palsy occurred in 3.5% and 0.6% of
patients for the VGLB and control groups, respectively.
These rates are consistent with other experiences
with the VGLB (6,10). Although most studies reported
complete resolution of the phrenic nerve palsy during
follow-up, in this study, the rate of persistent dia-
phragmatic paralysis at 1 year was 1.8%. However,
these rates are less than reported in STOP AF forFIGURE 4 VGLB Operator Learning Curve
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visually guided laser balloon.cryoballoon ablation: 13.5% and 2.5% for reversible and
persistent phrenic nerve paralysis (4).
Signiﬁcant PV stenosis with the VGLB did not occur
in this study and, indeed, has never been reportedwith
the VGLB. By contrast, the rate of signiﬁcant PV ste-
nosiswith RFA in this studywas 2.9% andwas reported
to be 3.1% for the cryoballoon in STOP AF. Of note, the
rates of these complications are consistent with those
reported for RFA (15,16).
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(A) Freedom from atrial ﬁbrillation (AF) and atrial tachycardia/ﬂutter at 1 year with antiarrhythmic drugs, radiofrequency ablation, and balloon catheters are
shown. The success rates shown are the drug-free single procedure success rates, with the exception of the radiofrequency ablation arm of ThermoCool AF
(asterisk), which included redo procedures during the blanking period. (B) The visually guided laser balloon is shown with the aiming and ablation spot of
light (arrow). (C) An endoscopic view is shown with the balloon positioned in the left superior pulmonary vein. The maneuverable aiming and ablation spot
is shown, and the left inferior pulmonary vein and left atrial appendage are seen.
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1359are expected, as demonstrated with the cryoballoon
experience (12). Similarly, learning curve effects were
evident with the VGLB. Although the favorable trends
in procedure times, complications, and efﬁcacy did not
reach statistical signiﬁcance (likely due to sample
size), another study with similar ﬁndings did demon-
strate statistically signiﬁcant improvement in some of
these parameters with >15-case previous experience
(6). Furthermore, a single-center study with a few very
experienced operators performing 150 VGLB ablations
demonstrated continued improvement in the ability to
acutely isolate PVs as well as in ﬂuoroscopy and pro-
cedure timeswhen the patients’ datawere divided into
tertiles (17).
Although none of the previous VGLB studies
demonstrated an improvement in freedom from AF
with increased operator experience, there is evidence
that ablation at higher doses of laser energy may
improve success (18). Bordignon et al. (18) demon-
strated that freedom from AF at 12 months was
60.0% with a low (5.5 to 8.5 W) laser energy ablation
strategy versus 83.0% with a high-dose (>8.5 W)
strategy (p ¼ 0.04). In the present study, laser energy
dosing was at operator discretion, with only very
general energy delivery guidelines. Therefore, the
effects of high- versus low-energy dosing cannot be
elucidated further in this study. Given this, and the
relative inexperience with VGLB ablation (versus
RFA) of even the most experienced operators in this
study, it is reasonable to expect further improved
procedure times, safety, and efﬁcacy with more
VGLB experience and a higher laser energy dosing
strategy.
CLINICAL PERSPECTIVE: COMPARISON OF BALLOON
ISOLATION TECHNOLOGIES. As compared with
cryoballoon-based PV isolation, the VGLB catheter has
the potential advantage of providing the operator
greater ﬂexibility with power titration. For example,
during ablation along the anterior aspects of the PVs,
where the tissue tends to be thicker, one can apply
more energy, whereas less energy can be delivered
along the posterior LA. This may be important because
excessive energy deposition along the posterior LA
may damage the esophagus, leading to gastric dysm-
otility and rarely, but devastatingly, atrio-esophageal
ﬁstula. Furthermore, during right superior PV isola-
tion, one has the capability of varying the location
of ablation with the VGLB catheter so as to avoid
damaging the phrenic nerve. Conversely, with the
cryoballoon catheter, if the phrenic nerve starts to
become affected, there is little one can do other than
ceasing cryoablation and switching to ablation using a
separate point-by-point ablation catheter.Of course, these are theoretical advantages; the true
relative safety and efﬁcacy of the cryoballoon and
VGLB catheters can only be determined by a prospec-
tive randomized trial, ideally conducted by operators
experienced with both technologies. Although no such
multicenter randomized comparative studies exist,
there is 1 single-center randomized study that com-
pared these 2 technologies (10). This study revealed:
1) similarly high rates of acute PV isolation and proce-
dure times between groups; 2) phrenic nerve palsy was
nonsigniﬁcantly higher with the cryoballoon (5.7% vs.
4.2%); and 3) freedom from AF at 12 months was
nonsigniﬁcantly higher with the VGLB (73.0% vs.
63.0%; p ¼ 0.18).
STUDY LIMITATIONS. The duration of AF necessary
to be considered a treatment failure in this study was
60 s rather than the standard 30-s duration. This may
have overestimated the success rates of VGLB abla-
tion. However, because this was a randomized com-
parison between the VGLB and RFA, both treatment
groups are likely to be similarly affected and the
ﬁndings of the study are unlikely to differ. The CT
and CMR studies used to ascertain PV stenosis were
interpreted at individual centers rather than a core
laboratory, and this may have implications on re-
ported PV stenosis rates. However, it should be noted
that no signiﬁcant PV stenosis has ever been reported
with the VGLB.
CONCLUSIONS
In this multicenter randomized controlled study,
VGLB ablation was noninferior to standard irrigated
RFA in terms of the primary efﬁcacy and safety end-
points. There was a 3.5% rate of phrenic nerve injury,
but no PV stenosis; both complications are frequent-
ly reported with other balloon technologies. Evalua-
tion of operator learning-curve effects demonstrated
that with increased operator experience, there was a
signiﬁcant improvement in ﬂuoroscopy time and
nonsigniﬁcant trends to improvement in procedure
time, efﬁcacy, and safety. The ﬁndings of this study
are encouraging, given the relative lack of operator
experience with the VGLB and a study protocol that
tended to favor RFA due to the ability to perform
ancillary ablation in the index procedure and redo
procedures during the blanking period, which were
not permitted in the VGLB arm.
REPRINT REQUESTS AND CORRESPONDENCE: Dr. Vivek
Y. Reddy, Icahn School of Medicine at Mount Sinai,
One Gustave L. Levy Place, Box 1030, New York, New
York 10029. E-mail: vivek.reddy@mountsinai.org.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Catheter
ablation of AF is generally more effective than AAD
therapy in maintaining sinus rhythm.
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: The laser balloon delivers adjustable
laser energy at operator-determined sites guided by
endoscopic visualization with results equivalent to RFA in
maintaining sinus rhythm in patients with AF.
TRANSLATIONAL OUTLOOK: Prospective compara-
tive studies are needed to identify the characteristics of
patients with AF that predict better responses to ablation
performed with one type of energy versus another.
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